for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BioNTech SE - ADR

BNTX.O

Latest Trade

70.36USD

Change

4.75(+7.24%)

Volume

2,874,259

Today's Range

67.00

 - 

71.29

52 Week Range

12.53

 - 

105.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
65.61
Open
67.00
Volume
2,874,259
3M AVG Volume
38.74
Today's High
71.29
Today's Low
67.00
52 Week High
105.00
52 Week Low
12.53
Shares Out (MIL)
226.26
Market Cap (MIL)
16,084.62
Forward P/E
-77.61
Dividend (Yield %)
--

Latest Developments

More

German Govt Will Not Influence Curevac's Corporate Policy - Ministry

Biontech And Pfizer Announce Completion Of Dosing For First Cohort Of Phase 1/2 Trial Of Covid-19 Vaccine Candidates In Germany

Biontech, Pfizer Announce Regulatory Approval From German Authority To Commence First Clinical Trial Of Covid-19 Vaccine Candidates

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About BioNTech SE - ADR

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. It develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Industry

Biotechnology & Drugs

Contact Info

An der Goldgrube 12

55131

Germany

+49.6131.90840

https://biontech.de/

Key Stats

2.56 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2019

0.1K

2020(E)

0.1K
EPS (EUR)

2019

-0.850

2020(E)

-0.815
Price To Earnings (TTM)
--
Price To Sales (TTM)
104.59
Price To Book (MRQ)
36.65
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
21.25
LT Debt To Equity (MRQ)
15.95
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Fauci says likely some degree of aerosol transmission of new coronavirus

The new coronavirus is likely spreading through the air to some degree, the top U.S. infectious disease official said on Friday, one day after the World Health Organization urged further studies on the ways the virus is transmitted.

RPT-Pfizer, BioNTech's COVID-19 vaccine expected to be ready for approval by year end - WSJ

BioNTech SE and Pfizer Inc's COVID-19 vaccine candidate is expected to be ready to seek regulatory approval by the end of 2020, the Wall Street Journal reported on Friday, citing the German biotech firm's chief executive officer.

Pfizer, BioNTech's COVID-19 vaccine expected to be ready for approval by year end: WSJ

BioNTech SE and Pfizer Inc's COVID-19 vaccine candidate is expected to be ready to seek regulatory approval by the end of 2020, the Wall Street Journal reported on Friday, citing the German biotech firm's chief executive officer.

RPT-BUZZ-U.S. stocks weekly: Fireworks!

(Repeats from Thursday, no changes to text. Adds chart) ** S&P 500 pops 4 straight days, finishes week up 4% ** At first it looked like the Nasdaq's bruising might lead to a break, but a vital sign is showing improvement ** While a golden cross now looms for the SPX ** Every...

Wall Street shifts bets to big pharma as COVID-19 vaccine race progresses

Wall Street is moving some bets on COVID-19 vaccines to large pharmaceutical companies with robust manufacturing capabilities, signaling that a love affair with small biotech firms might be ending after the sector’s best quarter in almost 20 years.

Tesla to make molecule printers for COVID-19 vaccine developer CureVac

Tesla Inc <TSLA.O> is building mobile molecule printers to help make the potential COVID-19 vaccine being developed by CureVac in Germany, the electric-car maker's CEO Elon Musk tweeted on Wednesday.

Blood cell damage may explain low oxygen levels; two vaccines show promise in early testing

The following is a brief roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.

Musk says Tesla is building 'RNA microfactories' for CureVac

Tesla Inc is building "RNA microfactories" for coronavirus vaccine developer CureVac in Germany, the electric carmaker's chief executive officer, Elon Musk, tweeted on Wednesday.

BioNTech and Pfizer's COVID-19 vaccine shows potential in human trial

A COVID-19 vaccine developed by German biotech firm BioNTech <BNTX.O> and U.S. pharmaceutical giant Pfizer <PFE.N> has shown potential and was found to be well tolerated in early-stage human trials, the companies said on Wednesday.

FACTBOX-COVID-19 vaccine candidates with early human-trial data

A COVID-19 vaccine developed by German biotech firm BioNTech and U.S. pharmaceutical giant Pfizer has shown potential and was found to be well tolerated in early-stage human trials, the companies said on Wednesday.

BioNTech and Pfizer's COVID-19 vaccine shows potential in human trial

A COVID-19 vaccine developed by German biotech firm BioNTech and U.S. pharmaceutical giant Pfizer has shown potential and was found to be well tolerated in early-stage human trials, the companies said on Wednesday.

FACTBOX-The race for a coronavirus vaccine

(Updates Inovio, Gamaleya vaccines; adds Bharat Biotech, PLA) June 30 (Reuters) - More than 100 vaccines are being developed and tested around the world to stop the COVID-19 pandemic, which has killed hundreds of thousands and ravaged the global economy. The following is...

Temasek-led investor group in $250 million vaccine bet on Germany's BioNTech

Singapore's state investor Temasek and other investors are injecting $250 million into German biotech company BioNTech <BNTX.O>, which is developing an experimental vaccine against the coronavirus with pharmaceutical giant Pfizer <PFE.N>.

BioNTech raises $250 million from investors including Temasek

BioNTech said Singapore's state investment company Temasek and other investors are injecting $250 million into the German biotech firm through a private placement.

CureVac starts trial of experimental coronavirus vaccine, eyes launch next year

Unlisted German biotech firm CureVac will become the second company after rival BioNTech <22UAy> to launch human trials of an experimental coronavirus vaccine in the country, eyeing a potential approval in mid-2021.

Factbox: CureVac's experimental coronavirus vaccine

Unlisted biotech firm CureVac on Wednesday become the second company after rival BioNTech <22UAy> to launch human trials of an experimental coronavirus vaccine in Germany, eyeing potential regulatory approval in mid-2021.

Factbox: CureVac's experimental coronavirus vaccine

Unlisted biotech firm CureVac on Wednesday become the second company after rival BioNTech <22UAy> to launch human trials of an experimental coronavirus vaccine in Germany, eyeing potential regulatory approval in mid-2021.

Germany not planning to take further biotech stakes after CureVac move - Scholz

Germany is not currently planning to take any further stakes in biotech firms, Finance Minister Olaf Scholz said on Wednesday after Berlin announced it would take a stake in German vaccine developer CureVac.

Coronavirus vaccine could be on market in mid-2021 - CureVac

A vaccine against the coronavirus pandemic by CureVac could be on the market in mid-2021, the unlisted German company said on Wednesday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up